The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

IMpower150 Data for Immunotherapy Quadruplet in EGFR-Mutant Lung Cancer

Edward B. Garon, MD
Published Online:4:26 PM, Tue February 5, 2019


Edward B. Garon, MD, director of thoracic oncology at the David Geffen School of Medicine at UCLA, discusses data from the IMpower150 trial where patients with EGFR-mutant lung cancer were randomized to 1 of 3 arms: a control of carboplatin, paclitaxel, and bevacizumab (Avastin), an arm replacing bevacizumab with atezolizumab (Tecentriq), and a third using all 4 agents.

Garon says the quadruplet regimen held the most benefit in respect to progression-free survival and also suggested an advantage in overall survival as well, despite a hazard ratio over 1. However, there was no clear benefit when atezolizumab was substituted for bevacizumab.

Despite not being a part of the quadruplet’s approval, Garon concludes that physicians are usually able to get this regimen to patients based on recommendations from the NCCN.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.